Expression of MiR-335 and its target metalloproteinase genes: clinical significance in breast cancer.
Breast cancer
MMP2
MMP9
clinicopathological characteristics
diagnosis
miR-335
Journal
Archives of physiology and biochemistry
ISSN: 1744-4160
Titre abrégé: Arch Physiol Biochem
Pays: England
ID NLM: 9510153
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
pubmed:
11
1
2020
medline:
31
5
2022
entrez:
11
1
2020
Statut:
ppublish
Résumé
Early diagnosis of breast cancer decreases mortality rate; therefore, novel diagnostic methods are urgently required. In this study, authors aimed to investigate the role of serum-derived miR-335 in breast cancer, and the expression of matrix metalloproteinase-2 (MMP2) and matrix metalloproteinase-9 (MMP9) and evaluating their feasibility and clinical utility as biomarkers for the early detection of breast cancer. Blood samples were collected from a total of 210 individuals who were enrolled in this study. The participants were divided into newly diagnosed breast cancer patients ( MiR 335 expression level was down-regulated in primary breast cancer group as compared to benign breast group and healthy individuals with 98% and 94.9% sensitivity and specificity, respectively. MMP2 and MMP9 showed significantly higher expression levels in breast cancer group as compared to both benign and healthy group and reporting 92.7% and 93% sensitivity, respectively. The relations between investigated markers and pathologic types, staging, grading, and lymph node involvement were significant with these factors. Expression level of miR-335 was decreased with increased MMP2 and MMP9 at significant level. MiR-335, MMP2, and MMP9 can be used as diagnostic markers in breast cancer.
Sections du résumé
BACKGROUND
UNASSIGNED
Early diagnosis of breast cancer decreases mortality rate; therefore, novel diagnostic methods are urgently required. In this study, authors aimed to investigate the role of serum-derived miR-335 in breast cancer, and the expression of matrix metalloproteinase-2 (MMP2) and matrix metalloproteinase-9 (MMP9) and evaluating their feasibility and clinical utility as biomarkers for the early detection of breast cancer.
MATERIALS AND METHODS
UNASSIGNED
Blood samples were collected from a total of 210 individuals who were enrolled in this study. The participants were divided into newly diagnosed breast cancer patients (
RESULTS
UNASSIGNED
MiR 335 expression level was down-regulated in primary breast cancer group as compared to benign breast group and healthy individuals with 98% and 94.9% sensitivity and specificity, respectively. MMP2 and MMP9 showed significantly higher expression levels in breast cancer group as compared to both benign and healthy group and reporting 92.7% and 93% sensitivity, respectively. The relations between investigated markers and pathologic types, staging, grading, and lymph node involvement were significant with these factors. Expression level of miR-335 was decreased with increased MMP2 and MMP9 at significant level.
CONCLUSION
UNASSIGNED
MiR-335, MMP2, and MMP9 can be used as diagnostic markers in breast cancer.
Identifiants
pubmed: 31922434
doi: 10.1080/13813455.2019.1703004
doi:
Substances chimiques
MIRN335 microRNA, human
0
MicroRNAs
0
MMP2 protein, human
EC 3.4.24.24
Matrix Metalloproteinase 2
EC 3.4.24.24
MMP9 protein, human
EC 3.4.24.35
Matrix Metalloproteinase 9
EC 3.4.24.35
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM